

DAFTAR PUSTAKA

- Al-Achkar, W., Moassass, F., Youssef, N., & Wafa, A. 2016. Correlation of p210 BCR-ABL transcript variants with clinical, parameters and disease outcome in 45 chronic myeloid leukemia patients. *Journal of BU ON.: official journal of the Balkan Union of Oncology*, 21(2), 444-449.
- Azad, N. A., Shah, Z. A., Pandith, A. A., Khan, M. S., Rasool, R., Rasool, J., & Aziz, S. A. 2018. Prognostic Implication of BCR-ABL Fusion Transcript Variants in Chronic Myeloid Leukemia (CML) Treated with Imatinib. A First of Its Kind Study on CML Patients of Kashmir. *Asian Pacific journal of cancer prevention: APJCP*, 19(6), 1479.
- Baccarani, M., Pileri, S., Steegmann, J. L., Muller, M., Soverini, S., Dreyling, M., & ESMO Guidelines Working Group. 2012. Chronic myeloid leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Annals of oncology*, 23(suppl_7), vii72-vii77.
- Balatzenko, G., Vundinti, B.R., Margarita, G. 2011. Correlation between the type of bcr-abl transcripts and blood cell counts in chronic myeloid leukemia—a possible influence of mdr1 gene expression. *Hematology Reports*, 3(e3): 5–9.
- Bhatia, R., Radich, J.P. 2008. Chronic Myeloid Leukemia. Dalam: Hoffman R, Benz EJ, Shattil S, Furie B, Silberstein LE, McGlave P, et al., editor. *Hematology Basic Principles and Practice*, Philadelphia, Elsevier Churchill Livingstone ; 1247–54.
- Burmeister, T., & Reinhardt, R. 2008. A multiplex PCR for improved detection of typical and atypical BCR–ABL fusion transcripts. *Leukemia research*, 32(4), 579-585.
- Chasseriau, J., Rivet, J., Bilan, F., Chomel, J. C., Guilhot, F., Bourmeyster, N., & Kitzis, A. 2004. Characterization of the different BCR-ABL transcripts with a single multiplex RT-PCR. *The Journal of molecular diagnostics*, 6(4), 343-347.
- Dahlan M.S., 2016. *Besar Sample Dalam Penelitian Kedokteran Dan Kesehatan*. Epidemiologi Indonesia, Jakarta.
- De Almeida Filho, T. P., Maia Filho, P. A., Barbosa, M. C., Dutra, L. L. A., de Castro, M. F., Duarte, F. B., ... & Lemes, R. P. G. 2019. Does BCR-ABL transcript type influence the prognosis of patients in chronic myelogenous leukemia chronic phase?. *Hematology, Transfusion and Cell Therapy*.
- Deb, P., Chakrabarti, P., Chakrabarty, S., Aich, R., Nath, U., Ray, S. S., & Chaudhuri, U. 2014. Incidence of BCR-ABL transcript variants in patients with chronic myeloid leukemia: Their correlation with presenting features, risk scores and response to treatment with imatinib mesylate. *Indian journal of medical and paediatric oncology: official journal of Indian Society of Medical & Paediatric Oncology*, 35(1), 26.
- Erdem, F dan Bilen, Y., 2012. Hematologic, cytogenetic, and molecular responses to imatinib therapy for chronic myeloid leukemia: a single-center experience in Turkey. *Turk J Med Sci* ; 42 (1): 31-38
- Fadjari dan Sukrisman. Leukemia Ganulositik Kronik Dalam Buku Ajar Ilmu Penyakit Dalam. 2014. Hal 2678-2682.

- Goh, H.-G., Hwang, J.-Y., Kim, S.-H., Lee, Y.-H., Kim, Y.-L., & Kim, D.-W. 2006. Comprehensive analysis of BCR-ABL transcript types in Korean CML patients using a newly developed multiplex RT-PCR. *Translational Research: The Journal of Laboratory and Clinical Medicine*, 148(5), 249–56.
- Goldman, J. M., & Melo, J. V. 2003. Chronic myeloid leukemia—advances in biology and new approaches to treatment. *New England Journal of Medicine*, 349(15), 1451-1464.
- Hai, A., Kizilbash, N. A., Zaidi, S. H. H., Alruwaili, J., & Shahzad, K. 2014. Differences in structural elements of Bcr-Abl oncoprotein isoforms in Chronic Myelogenous Leukemia. *Bioinformation*, 10(3), 108.
- Hariato, R., Boer, A., Satyadi, V., Samara, D., Sidarta, N., & Tjhin, P. 2004. Karakteristik Dimensi Antropometrik Statis Mahasiswa Fakultas Kedokteran Universitas Trisakti usia 19-21 tahun. *J Kedokteran Trisakti*, 23, 93-100.
- Harryanto, A., Hilman, T., Ikhwan, R., Arif, W., 2011, Clinical Characteristic, Hematologic Response and Gene Mutation of Patients with Chronic Phase Chronic Myeloid Leukemia (CML) to Imatinib at Cipto Mangunkusumo National Hospital. *Indonesian Journal of Cancer* Vol 5. No 4
- Inokuchi, K., Dan, K., Takatori, M., Takahuji, H., Uchida, N., Inami, M., ... & Shimada, T. 2003. Myeloproliferative disease in transgenic mice expressing P230 Bcr/Abl: longer disease latency, thrombocytosis, and mild leukocytosis. *Blood*, 102(1), 320-323.
- Iqbal, Z., Manzoor, F., Iqbal, M., Ali, S., Sheikh, N., Khan, M., *et al.* 2011. Frequency of Bcr-Abl fusion oncogene splice variants associated with chronic myeloid leukemia (CML). *Journal of Cancer Therapy* ; 2: 176–80.
- Jain, P., Kantarjian, H., Patel, K. P., Gonzalez, G. N., Luthra, R., Shamanna, R. K., ... & Pemmaraju, N. 2016. Impact of BCR-ABL transcript type on response and survival in patients with chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors. *Blood*, blood-2015.
- Jabbour, E., & Kantarjian, H. 2012. Chronic myeloid leukemia: 2012 update on diagnosis, monitoring, and management. *American journal of hematology*, 87(11), 1037-1045.
- Jabbour, E., & Kantarjian, H. 2016. Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring. *American journal of hematology*, 91(2), 252-265.
- Kang, Z. J., Liu, Y. F., Xu, L. Z., Long, Z. J., Huang, D., Yang, Y., ... & Liu, Q. 2016. The Philadelphia chromosome in leukemogenesis. *Chinese journal of cancer*, 35(1), 48.
- Kidney Disease Improving Global Outcome. 2016. KDIGO 2016 Clinical Practice Guideline Update on Diagnosis Evaluation, Prevention And Treatment of CKD-MBD. Int. Suppl. 2(4): 1-45.
- Li, S., Ilaria, R. L., Million, R. P., Daley, G. Q., & Van Etten, R. A. 1999. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity. *Journal of Experimental Medicine*, 189(9), 1399-1412.
- Lucas, C. M., Harris, R. J., Giannoudis, A., Davies, A., Knight, K., Watmough, S. J., ... & Clark, R. E. 2009. Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript. *Haematologica*, 94(10), 1362-1367.

- Menon, H. 2013. Issues in current management of chronic myeloid leukemia: Importance of molecular monitoring on long term outcome. *South Asian journal of cancer*, 2(1), 38.
- O'Brien, S. G., Guilhot, F., Larson, R. A., Gathmann, I., Baccarani, M., Cervantes, F., ... & Lechner, K. 2003. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. *New England Journal of Medicine*, 348(11), 994-1004.
- Ohsaka, A., Shiina, S., Kobayashi, M., Kudo, H., & Kawaguchi, R. 2002. Philadelphia chromosome-positive chronic myeloid leukemia expressing p190BCR-ABL. *Internal medicine*, 41(12), 1183-1187.
- Oshikawa, G., Kurosu, T., Arai, A., Murakami, N., & Miura, O. 2010. Clonal evolution with double Ph followed by tetraploidy in imatinib-treated chronic myeloid leukemia with e19a2 transcript in transformation. *Cancer Genetics and Cytogenetics*, 199(1), 56-61.
- Ou, J., Vergilio, J. A., & Bagg, A. 2008. Molecular diagnosis and monitoring in the clinical management of patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors. *American journal of hematology*, 83(4), 296-302.
- Pasternak, G., Hochhaus, A., Schultheis, B., & Hehlmann, R. 1998. Chronic myelogenous leukemia: molecular and cellular aspects. *Journal of cancer research and clinical oncology*, 124(12), 643-660.
- Perego, R. A., Costantini, M., Cornacchini, G., Gargantini, L., Bianchi, C., Pungolino, E., ... & Morra, E. 2000. The possible influences of B2A2 and B3A2 BCR/ABL protein structure on thrombopoiesis in chronic myeloid leukaemia. *European Journal of Cancer*, 36(11), 1395-1401.
- PERKI, 2015. *Buku Pedoman Tatalaksana Gagal Jantung*. Pengurus Besar Perhimpunan Dokter Spesialis Kardiovaskular Indonesia, Jakarta.
- Perrotti, D., Jamieson, C., Goldman, J., & Skorski, T. 2010. Chronic myeloid leukemia: mechanisms of blastic transformation. *The Journal of clinical investigation*, 120(7), 2254.
- Polampalli, S., Choughule, A., Negi, N., Shinde, S., Baisane, C., Amre, P., ... & Parikh, P. 2008. Analysis and comparison of clinicohematological parameters and molecular and cytogenetic response of two Bcr/Abl fusion transcripts. *Genet Mol Res*, 7(4), 1138-1149.
- Prihatni, D., Parwati, I., Sumantri, R., Roesli, R. M., & Nafsi, N. 2016. Fusi gen breakpoint cluster region Abelson kinase (bcr abl) dan uji hematologis rutin. *Indonesian Journal of Clinical Pathology and Medical Laboratory*, 20(1), 47-50.
- Quintás-Cardama, A., and Cortes, J. 2009. Molecular biology of bcr-abl1-positive chronic myeloid leukemia. *Blood*, 113(8), 1619-30.
- Reksodiputro, A. H., Tadjoeidin, H., Supandiman, I., Acang, N., Kar, A. S., & Bakta, I. M. 2015. Epidemiology study and mutation profile of patients with chronic myeloid leukemia (CML) in Indonesia. *J Blood Disord Transfus*, 6(271), 2.
- Ren, R. 2002. The molecular mechanism of chronic myelogenous leukemia and its therapeutic implications: studies in a murine model. *Oncogene*; 21(56):8629-42.
- Sillaber, C., Mayerhofer, M., Agis, H., Sagaster, V., Mannhalter, C., Sperr, W. R., ... & Valent, P. 2003. Chronic myeloid leukemia: pathophysiology, diagnostic parameters, and current treatment concepts. *Wiener Klinische Wochenschrift*, 115(13-14), 485-504.

- Skorski, T. 2011. Chronic myeloid leukemia cells refractory/resistant to tyrosine kinase inhibitors are genetically unstable and may cause relapse and malignant progression to the terminal disease state. *Leukemia & lymphoma*, 52(sup1), 23-29.
- Vasconcelos, A. P., Azevedo, I. F., Melo, F. C. B. C., Neves, W. B., Azevedo, A. C. A. C., & Melo, R. A. M. 2017. BCR-ABL1 transcript types showed distinct laboratory characteristics in patients with chronic myeloid leukemia. *Genetics and molecular research: GMR*, 16(2).
- Wetzler M, Marcucci G, Bloomfield CD. Acute and Chronic Myeloid Leukemia, in *Harrison's Principle of Internal Medicine*, 2012.
- Xiaomin, G., Yong, Z., Jinlan, P., Huiying, Q., Jiannong, C., Yongquan, X., ... & Yafang, W. 2015. Chronic myeloid leukemia with e14a3 BCR-ABL transcript: analysis of characteristics and prognostic significance. *Leukemia & lymphoma*, 56(12), 3343-3347.
- Yamamoto, E., Fujisawa, S., Hagihara, M., Tanaka, M., Fujimaki, K., Kishimoto, K., ... & Tachibana, T. 2014. European Treatment and Outcome Study score does not predict imatinib treatment response and outcome in chronic myeloid leukemia patients. *Cancer science*, 105(1), 105-109.